Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1237-1247

  Trbojevic Akmacic, Irena ^a   Ventham, Nicholas T ^b   Theodoratou, Evropi ^b   Vučković, Frano ^a   Kennedy, Nicholas A ^b   Krištić, Jasminka ^a   Nimmo, Elaine R ^b   Kalla, Rahul ^b   Drummond, Hazel ^b   Štambuk, Jerko ^a   Dunlop, Malcolm G ^b   Novokmet, Mislav ^a   Aulchenko, Yurii ^c,d   Gornik, Olga ^e   Campbell, Harry ^b   Pučić Baković, Maja ^a   Satsangi, Jack ^b   Lauc, Gordan ^a,e  

^a GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^d NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Crohn's disease; glycomics; IgG glycans; Inflammatory bowel disease; ulcerative colitis

Indexed keywords

GLYCAN; IMMUNOGLOBULIN G; GLYCOSYLATED IGG; POLYSACCHARIDE;

ADULT; ARTICLE; CHEMICAL COMPOSITION; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GLYCOSYLATION; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; ULCERATIVE COLITIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

ADULT; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; POLYSACCHARIDES; ROC CURVE;

EID: 84929900183     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000372     Document Type: Article

References (52)

1. Burisch J, Pedersen N,Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63:588-597.
2. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
3. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357-362.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
5. Franke A, Mcgovern DPB, Barrett JC, et al. Meta-analysis increases to 71 the tally of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
6. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
7. Lees CW; International IBD Genetics Consortium. Characterization of the ;40, 000 patient cohort of the International Inflammatory Bowel Disease genetics consortium (IIBDGC). J Crohns Colitis. 2013;7:S4.
8. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;490:119-124.
9. Theodoratou E, Campbell H, Ventham NT, et al. The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:588-600.
10. Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143: 672-676.
11. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13: 448-462.
12. Gornik O, Pavic T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins-implications on evolution and disease. Biochim Biophys Acta. 2012;1820:1318-1326.
13. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers. 2008;25:267-278.
14. Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10: 352-361.
15. Johansson ME, Gustafsson JK, Holmén-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014; 63:281-291.
16. Fu J, Wei B, Wen T, et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 2011;121:1657-1666.
17. Vander Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-129.
18. Miyahara K, Nouso K, Saito S, et al. Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One. 2013;8:e74861.
19. Pucic M, Knezevic A, Vidic J, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10:M111.
20. Menni C, Keser T, Mangino M, et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One. 2013;8: e82558.
21. Lauc G, Huffman JE, Pucic M, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9:e1003225.
22. Fujii S, Nishiura T, Nishikawa A, et al. Structural heterogeneity of sugar chains in immunoglobulin G. Conformation of immunoglobulin G molecule and substrate specificities of glycosyltransferases. J Biol Chem. 1990; 265:6009-6018.
23. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res. 2006;12:2879-2887.
24. Masuda K, Kubota T, Kaneko E, et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol. 2007;44: 3122-3131.
25. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313: 670-673.
26. Scanlan CN, Burton DR, Dwek RA. Making autoantibodies safe. Proc Natl Acad Sci USA. 2008;105:4081-4082.
27. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9.
28. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
29. Theodoratou E, Kyle J, Cetnarskyj R, et al. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16: 684-693.
30. Bates D, Mächler M, Bolker B, et al. Fitting linear mixed-effects models using lme4. R News. 2005;5:27-30.
31. Novokmet M, Lukic E, Vuckovic F, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep. 2014;4:4347.
32. Aulchenko YS, Ripke S, Isaacs A, et al. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23:1294-1296.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
34. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control. 1974;19:716-723.
35. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
36. Fawcett T. ROC graphs: notes and practical considerations for researchers. Mach Learn. 2004;31:1-38.
37. Shinzaki S, Iijima H, Nakagawa T, et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol. 2008;103:1173-1181.
38. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
39. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176-189.
40. Ercan A, Cui J, Chatterton DE, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62:2239-2248.
41. Rombouts Y, Ewing E, van de Stadt LA, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. 2015;74:234-241.
42. Ito K, Furukawa J, Yamada K, et al. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies. J Immunol. 2014;192:581-588.
43. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125-139.
44. Mesko B, Poliska S, Szamosi S, et al. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. J Rheumatol. 2012;39:916-928.
45. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgRIIB and dectin-1. Nat Med. 2012;18:1401-1406.
46. Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev. 2012;12:275-280.
47. Dias AM, Dourado J, Lago P, et al. Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Hum Mol Genet. 2014;23:2416-2427.
48. Debré M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342:945-949.
49. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110-113.
50. Preithner S, Elm S, Lippold S, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibodydependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol. 2006;43:1183-1193.
51. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem. 2003;278:3466-3473.
52. Ogata S, Shimizu C, Franco A, et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One. 2013;8:e81448.